Caris Life Sciences Showcases AI and Precision Medicine Innovations at ESMO 2026
Caris Life Sciences Showcases AI and Precision Medicine Innovations at ESMO 2026
Caris Life Sciences®, a prominent TechBio company, is set to make waves at the upcoming European Society for Medical Oncology (ESMO) Congress 2026, which will be held from October 23 to 27 in Madrid, Spain. The organization will present eight significant research studies highlighting the transformative potential of artificial intelligence, multi-omics, and precision medicine in treating various cancers.
The research shared by Caris will focus on AI's ability to predict treatment outcomes, assess risks, and discover biomarkers across multiple tumor types. Two studies spearheaded by Caris concern AI applications for breast cancer, while six others come from collaborations involving members of the Caris Precision Oncology Alliance® (Caris POA). These presentations will delve into the realms of breast, lung, endometrial, melanoma, and immuno-oncology research, showcasing how thorough molecular profiling and clinico-genomic data can illuminate new biological insights as well as personalize treatment options for patients.
Dr. James Hamrick, Chairman of the Caris POA, expressed his enthusiasm, stating, "Artificial intelligence is revolutionizing our understanding of cancer biology and simultaneously enhancing our capacity to predict responses to therapies like never before. The presentations we will showcase at ESMO 2026 exemplify the integration of AI, detailed molecular profiling, and real-world clinical data, all aimed at unveiling insightful, clinically relevant findings that can steer precise treatment choices for patients."
Caris-Led Studies
1. AI in Breast Cancer Treatment:
- Poster 178P: This study explores the Caris CapeAI model's effectiveness in predicting treatment responses among ER+ breast cancer patients using Capecitabine.
- Date and Time: Sunday, 25 October 2026, 12:00 – 12:45 PM (Madrid time).
- Authors: Javier Pascual Lopez, Chen Sun, Miguel J. Gil, and others.
2. Extended Endocrine Therapy:
- Poster 217P: Focusing on HR+ early breast cancer, this study investigates how multimodal AI approaches could assist in assessing risks and benefits regarding extended endocrine therapy.
- Date and Time: Sunday, 25 October 2026, 12:00 – 12:45 PM (Madrid time).
- Authors: Eleftherios P. Mamounas, Md Ashequr Rahman, Ming Chen, and others.
Collaborative Studies with Caris Precision Oncology Alliance
Additionally, numerous collaborative studies will present under the Caris POA:
1. EGFR-Mutated NSCLC:
- Poster 3285P: This research characterizes differences in survival rates related to G-protein coupled estrogen receptors in EGFR-mutated non-small cell lung cancer (NSCLC).
- Date and Time: Friday, 23 October 2026, 3:15 – 4:00 PM.
- Authors: Robert Hsu, Mercy Kehinde-Ige, Sharon Wu, and others.
2. Endometrial Cancer Immune Microenvironment:
- Poster 1296P: This study looks at how genomic scars indicative of homologous recombination deficiency relate to the tumor immune microenvironment in endometrial cancer.
- Date and Time: Monday, 26 October 2026, 12:00 – 12:45 PM.
- Authors: Hiromichi Nakajima, Kenichi Harano, Sharon Wu, and others.
3. T-Cell Exhaustion Signature:
- Poster 4395P: Investigating a 25-gene signature tied to T-cell exhaustion and its potential to refine predictions of immunotherapy benefits.
- Date and Time: Friday, 23 October 2026, 3:15 – 4:00 PM.
- Authors: Nathan El Ghazzi, Andrew Elliott, George Sledge, and others.
What's Next for Caris?
The booth #1021 at the ESMO Congress will feature additional highlights of ongoing research at the Caris exhibit, focusing on the future of precision oncology and biomarker-driven research. The Caris Precision Oncology Alliance is actively charting new paths to enhance patient care through innovative scientific programs that promise to reshape precision medicine.
As Caris Life Sciences fuels advancements in healthcare with AI and data-driven insights, its commitment to improving human health through innovative solutions continues to be at the forefront. With a global presence and collaboration with leading healthcare providers, Caris aims not just to contribute to cancer treatment advancements but also to redefine them as the landscape of precision medicine evolves.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.